Notably, CCS1477 has shown potent activity in suppressing PCa cell growth in vitro and in vivo, in part by downregulating AR and MYC expression, and is currently under evaluation in a first-in-human phase I clinical trial for advanced PCa (16). Here, MYC is linked to posterior cortical atrophy.